Morgan Ventures has reappointed Kuldeep Kumar Dhar as its Managing Director for a five-year term, effective from August 14, 2026, to August 13, 2031. The Board of Directors approved the move on August 7, 2026, following recommendations from the Nomination and Remuneration Committee. This governance update arrives as the company navigates a period of financial stress, having reported a net loss of ₹234.11 lakh in Q1FY26 compared to a profit of ₹104.58 lakh in the same period last year.

The reappointment is subject to shareholder approval at the company’s 39th Annual General Meeting (AGM), scheduled for September 2, 2026. In compliance with Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A(7) of Part A of Schedule III, Morgan Ventures submitted an intimation to the Bombay Stock Exchange (BSE). The filing also references SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, which mandates detailed disclosures for such appointments.

Kuldeep Kumar Dhar brings over five decades of experience in business development, arbitration, accounts, legal affairs, and management. He holds a graduate degree and is a CA Inter by qualification. According to the disclosure, he is not related to any other director of the company and is not debarred from holding office by any SEBI order or other authority. His leadership will be critical as the company addresses rising interest costs and declining investment income.

Governance and Regulatory Compliance

The Board’s decision aligns with standard corporate governance practices, ensuring continuity in executive leadership. The intimation filed with the BSE includes specific disclosures required under BSE Circular LIST/COMP/14/2018-19 and NSE Circular NSE/CML/2018/24, both dated June 20, 2018. These regulations require companies to confirm that appointed directors are not barred from serving in such capacities.

Financial Context

The leadership change occurs against a backdrop of deteriorating financial performance. In Q1FY26, total income fell to ₹285.44 lakh from ₹552.53 lakh in Q1FY25, while expenses surged to ₹604.24 lakh from ₹486.14 lakh. Interest payments rose significantly to ₹441.95 lakh, exceeding total income and contributing to an operating loss before tax of ₹318.80 lakh. The debt-equity ratio increased to 2.32 from 1.88, highlighting heightened leverage risks.

What the Numbers Show

The reappointment of Kuldeep Kumar Dhar signals management’s intent to stabilize operations amid financial headwinds. With interest costs consuming more than half of total income, the new term will focus on debt servicing and improving investment returns. The upcoming AGM will also see votes on material related-party transactions with Morgan Securities & Credits Private Limited and Peacock Chemicals Private Limited, involving loans and services up to ₹200 crore each. These approvals are crucial for maintaining liquidity and operational continuity in FY27.

Morgan Ventures Limited has approved the re-appointment of Dr. Sanjiv Bansal as an Independent Director for a second term of five years, effective June 17, 2026. The decision, taken by the Board of Directors on May 29, 2026, is subject to the approval of the company's shareholders. This move ensures continuity in the company's governance structure as Dr. Bansal completes his first term.

The re-appointment follows the recommendation of the Nomination and Remuneration Committee. Dr. Bansal's new term will commence on June 17, 2026, and conclude on June 17, 2031. He will not be liable to retire by rotation during this period. The company disclosed these details in a filing submitted to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dr. Sanjiv Bansal is a physician by profession, having completed his education at the University of Mysore. He brings extensive experience in diagnosing and managing a wide range of medical conditions. Beyond his medical practice, he owns Bansal Hospitals in Delhi and possesses significant management experience through directorships in various companies.

The disclosure confirms that Dr. Bansal is not related to any other director on the Board of Morgan Ventures Limited. Furthermore, he is not debarred from holding the office of director by any order of the Securities and Exchange Board of India or any other regulatory authority, as required under relevant circulars.

Details of Re-appointment